Evoq Remedies Ltd
Fundamental Score
Evoq Remedies Ltd Share Price Live NSE/BSE
Profitability Metrics
Return on Equity
Return on Capital Employed
Operating Profit Margin (5Y)
Dividend Yield
Valuation Metrics
Price to Earnings
Market Capitalization
Industry P/E
Growth Metrics
YoY Quarterly Profit Growth
YoY Quarterly Sales Growth
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Financial Health
Debt to Equity
Interest Coverage
Free Cash Flow (5Y)
Ownership Structure
Promoter Holding
FII Holding
DII Holding
Pledged Percentage
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Market Data Analysis & Educational Insights
Educational evaluation of EVOQ across key market metrics for learning purposes.
Positive Indicators
4 factors identified
Attractive Valuation (P/E: 4.54 vs Industry: 35.45)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity if fundamentals support the business case.
Robust Profit Growth (103.09%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture. This suggests positive business trajectory.
Debt-Free Balance Sheet (D/E: 0.00)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns and flexibility for growth investments.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral, reducing forced-selling risk.
Analysis: Absence of share pledging eliminates potential forced-selling pressure during market stress.
Risk Factors
9 factors identified
Below-Average Return on Equity (0.26%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (0.35%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation. Review business model and competitive positioning.
Margin Pressure Concerns (-8.24%)
Observation: Operating margins are below industry standards.
Analysis: OPM <5% may indicate pricing pressures or cost management challenges. Monitor for operational improvements.
Weak Earnings Growth (-67.52% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation. Consider growth catalysts and competitive positioning.
Negative Free Cash Flow (₹-40.33 Cr over 5Y)
Observation: Cash outflows exceed inflows, indicating capital intensity or working capital issues.
Analysis: Negative FCF requires analysis of capital expenditure cycle and working capital management efficiency.
Low Promoter Commitment (11.21%)
Observation: Reduced promoter stake may indicate limited confidence.
Analysis: Low promoter holding may raise questions about management commitment and long-term vision alignment.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints. Assess capital allocation strategy.
Very Low ROE
Observation: Poor capital utilization and shareholder returns.
Analysis: ROE below 5% suggests significant inefficiencies in capital deployment.
Small Market Cap
Observation: Higher investment risk due to limited size.
Analysis: Small-cap stocks typically carry higher volatility and liquidity risks.
Financial Statements
Comprehensive financial data for Evoq Remedies Ltd
About EVOQ
Business Overview
Evoq Remedies Limited engages in the pharmaceutical business in India. The company trades in and acts as a commission agent for pharmaceutical products. It also manufactures, distributes, and exports commercial grade, refined, pale pressed grade, and first pressed degummed castor oils; castor oil and de oil cakes; and high protein castor meals. Evoq Remedies Limited was incorporated in 2010 and is based in Ahmedabad, India.
Company Details
Key Leadership
Latest News
EVOQ Stock Details & Analysis
Key Financial Metrics
Growth & Valuation
Frequently Asked Questions
What is the current price of Evoq Remedies Ltd (EVOQ)?
As of 29 Jan 2026, 10:34 am IST, Evoq Remedies Ltd (EVOQ) is currently trading at ₹3.02. The stock has a market capitalization of ₹7.99 (Cr).
Is EVOQ share price Overvalued or Undervalued?
EVOQ is currently trading at a P/E ratio of 4.54x, compared to the industry average of 35.45x. Based on this relative valuation, the stock appears to be Undervalued against its sector peers.
What factors affect the Evoq Remedies Ltd share price?
Key factors influencing EVOQ's price include its quarterly earnings growth (Sales Growth: N/A%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Evoq Remedies Ltd a good stock for long-term investment?
Evoq Remedies Ltd shows a 5-year Profit Growth of N/A% and an ROE of 0.26%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.00 before investing.
How does Evoq Remedies Ltd compare with its industry peers?
Evoq Remedies Ltd competes with major peers in the Trading & Distributors. Investors should compare EVOQ's P/E of 4.54x and ROE of 0.26% against the industry averages to determine its competitive standing.
What is the P/E ratio of EVOQ and what does it mean?
EVOQ has a P/E ratio of 4.54x compared to the industry average of 35.45x. The Price-to-Earnings (P/E) ratio is calculated by dividing the current share price by earnings per share (EPS). This means investors are paying ₹5 for every ₹1 of annual earnings.
How is EVOQ performing according to Bull Run's analysis?
EVOQ has a Bull Run fundamental score of 20.3/100, which indicates concerns that require careful analysis. This comprehensive rating is based on 15+ financial parameters including profitability, growth metrics, and valuation ratios.
What sector and industry does EVOQ belong to?
EVOQ operates in the Trading & Distributors industry. This classification helps understand the competitive landscape and sector-specific trends affecting Evoq Remedies Ltd.
What is Return on Equity (ROE) and why is it important for EVOQ?
EVOQ has an ROE of 0.26%, which suggests challenges in generating returns from shareholders' equity. Return on Equity measures how efficiently Evoq Remedies Ltd generates profits from shareholders' equity.
How is EVOQ's debt-to-equity ratio and what does it indicate?
EVOQ has a debt-to-equity ratio of 0.00, which indicates conservative financing with low financial risk. A ratio below 1.0 generally indicates conservative financing.
What is EVOQ's dividend yield and is it a good dividend stock?
EVOQ offers a dividend yield of 0.00%, which means you receive ₹0.00 annual dividend for every ₹100 invested.
How has EVOQ grown over the past 5 years?
EVOQ has achieved 5-year growth rates of: Sales Growth 5.33%, Profit Growth N/A%, and EPS Growth -67.52%.
What is the promoter holding in EVOQ and why does it matter?
Promoters hold 11.21% of EVOQ shares, with 0.00% of promoter shares pledged. High promoter holding often indicates strong management confidence.
What is EVOQ's market capitalization category?
EVOQ has a market capitalization of ₹8 crores, placing it in the Small-cap category.
How volatile is EVOQ stock?
EVOQ has a beta of N/A. A beta > 1 suggests the stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is the 52-week high and low for EVOQ?
EVOQ has a 52-week high of ₹N/A and low of ₹N/A.
What is EVOQ's operating profit margin trend?
EVOQ has a 5-year average Operating Profit Margin (OPM) of -8.24%, indicating the company's operational efficiency.
How is EVOQ's quarterly performance?
Recent quarterly performance shows YoY Sales Growth of N/A% and YoY Profit Growth of 103.09%.
What is the institutional holding pattern in EVOQ?
EVOQ has FII holding of 0.00% and DII holding of 0.00%. Significant institutional holding often suggests professional confidence in the stock.